Reassessment of corticospinal tract regeneration in Nogo-deficient mice

Jae Lee, Andrea F. Chan, Sen M. Luu, Yuhong Zhu, Carole Ho, Marc Tessier-Lavigne, Binhai Zheng

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The myelin-derived neurite growth inhibitor Nogo has been proposed to play a major role in blocking axon regeneration in the CNS after injuries. However, past studies have produced mixed results regarding the regenerative phenotype of various Nogo-deficient mouse lines after experimental spinal cord injury. Two lines did not display enhanced corticospinal tract (CST) regeneration, and one displayed modest regeneration. A fourth line, a Nogo-A,B gene-trap mutant, was instead reported to exhibit extensive CST regeneration, but the results were later found to be inadvertently confounded with an axon labeling artifact. Of the four Nogo mutant lines studied so far, three continue to express some isoform(s) of Nogo, leaving open the question whether any remaining Nogo protein contributes to the modest regenerative phenotype reported in some. The remaining Nogo mutant line studied was confounded by the unexplained rescue of embryonic lethality associated with this mutation. To gain a better understanding of the contribution of Nogo as an inhibitor of regeneration of CNS axons, and particularly CST axons, we reanalyzed the Nogo-A,B gene-trap mutant line and analyzed a novel, fully viable Nogo deletion mutant line that is null for all known isoforms of Nogo. Our analyses failed to reveal any enhanced CST regeneration after experimental spinal cord injury in either line. These results indicate that Nogo alone does not account for lack of CST regeneration and have implications for current therapeutic development for spinal cord injury in humans by targeting Nogo.

Original languageEnglish
Pages (from-to)8649-8654
Number of pages6
JournalJournal of Neuroscience
Volume29
Issue number27
DOIs
StatePublished - Jul 8 2009
Externally publishedYes

Fingerprint

Pyramidal Tracts
Regeneration
Axons
Spinal Cord Injuries
Protein Isoforms
Phenotype
Growth Inhibitors
Neurites
Myelin Sheath
Artifacts
Genes
Mutation
Wounds and Injuries

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Lee, J., Chan, A. F., Luu, S. M., Zhu, Y., Ho, C., Tessier-Lavigne, M., & Zheng, B. (2009). Reassessment of corticospinal tract regeneration in Nogo-deficient mice. Journal of Neuroscience, 29(27), 8649-8654. https://doi.org/10.1523/JNEUROSCI.1864-09.2009

Reassessment of corticospinal tract regeneration in Nogo-deficient mice. / Lee, Jae; Chan, Andrea F.; Luu, Sen M.; Zhu, Yuhong; Ho, Carole; Tessier-Lavigne, Marc; Zheng, Binhai.

In: Journal of Neuroscience, Vol. 29, No. 27, 08.07.2009, p. 8649-8654.

Research output: Contribution to journalArticle

Lee, J, Chan, AF, Luu, SM, Zhu, Y, Ho, C, Tessier-Lavigne, M & Zheng, B 2009, 'Reassessment of corticospinal tract regeneration in Nogo-deficient mice', Journal of Neuroscience, vol. 29, no. 27, pp. 8649-8654. https://doi.org/10.1523/JNEUROSCI.1864-09.2009
Lee, Jae ; Chan, Andrea F. ; Luu, Sen M. ; Zhu, Yuhong ; Ho, Carole ; Tessier-Lavigne, Marc ; Zheng, Binhai. / Reassessment of corticospinal tract regeneration in Nogo-deficient mice. In: Journal of Neuroscience. 2009 ; Vol. 29, No. 27. pp. 8649-8654.
@article{7524cd32088e4b0abcd779670b7a495b,
title = "Reassessment of corticospinal tract regeneration in Nogo-deficient mice",
abstract = "The myelin-derived neurite growth inhibitor Nogo has been proposed to play a major role in blocking axon regeneration in the CNS after injuries. However, past studies have produced mixed results regarding the regenerative phenotype of various Nogo-deficient mouse lines after experimental spinal cord injury. Two lines did not display enhanced corticospinal tract (CST) regeneration, and one displayed modest regeneration. A fourth line, a Nogo-A,B gene-trap mutant, was instead reported to exhibit extensive CST regeneration, but the results were later found to be inadvertently confounded with an axon labeling artifact. Of the four Nogo mutant lines studied so far, three continue to express some isoform(s) of Nogo, leaving open the question whether any remaining Nogo protein contributes to the modest regenerative phenotype reported in some. The remaining Nogo mutant line studied was confounded by the unexplained rescue of embryonic lethality associated with this mutation. To gain a better understanding of the contribution of Nogo as an inhibitor of regeneration of CNS axons, and particularly CST axons, we reanalyzed the Nogo-A,B gene-trap mutant line and analyzed a novel, fully viable Nogo deletion mutant line that is null for all known isoforms of Nogo. Our analyses failed to reveal any enhanced CST regeneration after experimental spinal cord injury in either line. These results indicate that Nogo alone does not account for lack of CST regeneration and have implications for current therapeutic development for spinal cord injury in humans by targeting Nogo.",
author = "Jae Lee and Chan, {Andrea F.} and Luu, {Sen M.} and Yuhong Zhu and Carole Ho and Marc Tessier-Lavigne and Binhai Zheng",
year = "2009",
month = "7",
day = "8",
doi = "10.1523/JNEUROSCI.1864-09.2009",
language = "English",
volume = "29",
pages = "8649--8654",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "27",

}

TY - JOUR

T1 - Reassessment of corticospinal tract regeneration in Nogo-deficient mice

AU - Lee, Jae

AU - Chan, Andrea F.

AU - Luu, Sen M.

AU - Zhu, Yuhong

AU - Ho, Carole

AU - Tessier-Lavigne, Marc

AU - Zheng, Binhai

PY - 2009/7/8

Y1 - 2009/7/8

N2 - The myelin-derived neurite growth inhibitor Nogo has been proposed to play a major role in blocking axon regeneration in the CNS after injuries. However, past studies have produced mixed results regarding the regenerative phenotype of various Nogo-deficient mouse lines after experimental spinal cord injury. Two lines did not display enhanced corticospinal tract (CST) regeneration, and one displayed modest regeneration. A fourth line, a Nogo-A,B gene-trap mutant, was instead reported to exhibit extensive CST regeneration, but the results were later found to be inadvertently confounded with an axon labeling artifact. Of the four Nogo mutant lines studied so far, three continue to express some isoform(s) of Nogo, leaving open the question whether any remaining Nogo protein contributes to the modest regenerative phenotype reported in some. The remaining Nogo mutant line studied was confounded by the unexplained rescue of embryonic lethality associated with this mutation. To gain a better understanding of the contribution of Nogo as an inhibitor of regeneration of CNS axons, and particularly CST axons, we reanalyzed the Nogo-A,B gene-trap mutant line and analyzed a novel, fully viable Nogo deletion mutant line that is null for all known isoforms of Nogo. Our analyses failed to reveal any enhanced CST regeneration after experimental spinal cord injury in either line. These results indicate that Nogo alone does not account for lack of CST regeneration and have implications for current therapeutic development for spinal cord injury in humans by targeting Nogo.

AB - The myelin-derived neurite growth inhibitor Nogo has been proposed to play a major role in blocking axon regeneration in the CNS after injuries. However, past studies have produced mixed results regarding the regenerative phenotype of various Nogo-deficient mouse lines after experimental spinal cord injury. Two lines did not display enhanced corticospinal tract (CST) regeneration, and one displayed modest regeneration. A fourth line, a Nogo-A,B gene-trap mutant, was instead reported to exhibit extensive CST regeneration, but the results were later found to be inadvertently confounded with an axon labeling artifact. Of the four Nogo mutant lines studied so far, three continue to express some isoform(s) of Nogo, leaving open the question whether any remaining Nogo protein contributes to the modest regenerative phenotype reported in some. The remaining Nogo mutant line studied was confounded by the unexplained rescue of embryonic lethality associated with this mutation. To gain a better understanding of the contribution of Nogo as an inhibitor of regeneration of CNS axons, and particularly CST axons, we reanalyzed the Nogo-A,B gene-trap mutant line and analyzed a novel, fully viable Nogo deletion mutant line that is null for all known isoforms of Nogo. Our analyses failed to reveal any enhanced CST regeneration after experimental spinal cord injury in either line. These results indicate that Nogo alone does not account for lack of CST regeneration and have implications for current therapeutic development for spinal cord injury in humans by targeting Nogo.

UR - http://www.scopus.com/inward/record.url?scp=67650476495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650476495&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.1864-09.2009

DO - 10.1523/JNEUROSCI.1864-09.2009

M3 - Article

C2 - 19587271

AN - SCOPUS:67650476495

VL - 29

SP - 8649

EP - 8654

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 27

ER -